Cabozantinib a Possible New Standard in Second-line Metastatic RCCCabozantinib a Possible New Standard in Second-line Metastatic RCC

Dr David Graham reviews the METEOR trial in metastatic renal cell carcinoma, one of the most important studies on genitourinary malignancies presented at ASCO 2016. Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news